SwissNeurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
https://european-biotechnology.com/wp-content/uploads/2024/04/Neurimmune.jpg10661600Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-01-18 10:06:412024-04-04 16:47:56Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
https://european-biotechnology.com/wp-content/uploads/2024/04/Evotec_HQ.jpg12522000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-01-18 09:54:122024-04-04 16:47:57Evotec and Lilly to collaborate in metabolic diseases
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-01-12 11:44:142024-07-18 14:24:29Onxeo with interim CEO
After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.
https://european-biotechnology.com/wp-content/uploads/2024/04/Sound_Bioventures.jpeg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-01-04 10:54:552022-01-04 10:54:55Sound Bioventures Fund I AB closes at €110m
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
Latest NewsSwiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
Evotec and Lilly to collaborate in metabolic diseases
Latest NewsGerman Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
Protagen, BioAnalytix and GeneWerk launch ProtaGene
Latest NewsFollowing their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene.
Onxeo with interim CEO
AppointmentsParis-based Onxeo S.A. has started the new year with an interim CEO. Julien Miara has taken over the position.
BioNTech SE licences Cresendo Bio’s Humabody technology
Latest NewsBioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
Latest NewsAfter Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune inks US-$760 deal with AstraZeneca
Latest NewsNeurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Latest NewsSwiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Latest NewsModerna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at €110m
Latest NewsNovo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.